Journal
MARINE DRUGS
Volume 19, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/md19010024
Keywords
marine drugs; neurodegenerative diseases; Parkinson’ s disease; Alzheimer’ s disease; brain; antioxidants
Categories
Funding
- RIA
Ask authors/readers for more resources
Marine habitats contain diverse bioactive compounds with pharmaceutical potential, synthesized by marine organisms to survive extreme environmental conditions. Compounds like xanthines, bryostatin, and 11-dehydrosinulariolide show promising neuroprotective effects in neurodegenerative diseases. Studies suggest these marine compounds can serve as potential adjuvant therapies for neurodegenerative disorders due to their antioxidant, anti-inflammatory, and anti-apoptotic properties.
Marine habitats offer a rich reservoir of new bioactive compounds with great pharmaceutical potential; the variety of these molecules is unique, and its production is favored by the chemical and physical conditions of the sea. It is known that marine organisms can synthesize bioactive molecules to survive from atypical environmental conditions, such as oxidative stress, photodynamic damage, and extreme temperature. Recent evidence proposed a beneficial role of these compounds for human health. In particular, xanthines, bryostatin, and 11-dehydrosinulariolide displayed encouraging neuroprotective effects in neurodegenerative disorders. This review will focus on the most promising marine drugs' neuroprotective potential for neurodegenerative disorders, such as Parkinson's and Alzheimer's diseases. We will describe these marine compounds' potential as adjuvant therapies for neurodegenerative diseases, based on their antioxidant, anti-inflammatory, and anti-apoptotic properties.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available